Alnylam Names TTR Amyloidosis Rx as Next IND Candidate, Posts Higher Q2 Losses on Increased Costs

Alnylam's selection of ALN-TTR as its next IND candidate comes as no surprise after a company official told RNAi News earlier this summer that it was "highly likely" that the company would choose the drug over other candidates.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.